Novo Nordisk A/S (NYSE:NVO) Position Reduced by Mutual Advisors LLC

Mutual Advisors LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 10.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 28,227 shares of the company’s stock after selling 3,317 shares during the period. Mutual Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,345,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Wendell David Associates Inc. increased its holdings in Novo Nordisk A/S by 0.3% in the fourth quarter. Wendell David Associates Inc. now owns 76,847 shares of the company’s stock valued at $6,610,000 after buying an additional 225 shares during the last quarter. Traynor Capital Management Inc. increased its holdings in shares of Novo Nordisk A/S by 4.8% in the 4th quarter. Traynor Capital Management Inc. now owns 320,162 shares of the company’s stock valued at $27,540,000 after acquiring an additional 14,758 shares during the last quarter. Wesbanco Bank Inc. raised its position in shares of Novo Nordisk A/S by 22.9% during the 4th quarter. Wesbanco Bank Inc. now owns 103,116 shares of the company’s stock valued at $8,870,000 after acquiring an additional 19,224 shares in the last quarter. SG Americas Securities LLC lifted its stake in Novo Nordisk A/S by 379.8% during the fourth quarter. SG Americas Securities LLC now owns 107,725 shares of the company’s stock worth $9,267,000 after purchasing an additional 85,272 shares during the last quarter. Finally, Phillips Wealth Planners LLC boosted its holdings in Novo Nordisk A/S by 8.0% in the fourth quarter. Phillips Wealth Planners LLC now owns 2,750 shares of the company’s stock worth $237,000 after purchasing an additional 203 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO opened at $81.36 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The business’s 50 day moving average is $96.10 and its 200-day moving average is $115.79. The stock has a market cap of $365.09 billion, a PE ratio of 26.33, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on NVO shares. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.